1. Scrip
  2. >>Business

Alexion's R&D Plans At Increased Pace With Rhythm Voucher

Follows Last Month's Acquisition Agreement With AstraZeneca

 
• By John Davis

After last month’s news of its proposed acquisition by AstraZeneca, Alexion Pharmaceuticals has bought a priority review voucher from Rhythm Pharmaceuticals, which would speed one of its development projects towards the marketplace.

vector image of long term exposure to light vehicles
Speeding Development Plans • Source: Shutterstock

Alexion Pharmaceuticals Inc.’s attractions for its likely acquirer AstraZeneca PLC now include a rare pediatric disease priority review voucher (PRV), which Alexion is buying from Rhythm Pharmaceuticals, Inc. for $100m. Rhythm announced the sale on 5 January, when its share price rose by 4%. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business